<DOC>
	<DOC>NCT02757989</DOC>
	<brief_summary>Comparison of survival in patients with or without a matched donor at 36 months</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk</brief_title>
	<detailed_description>Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation. Patients without a matched donor received the best available treatment. All patients will be followed at least 36 months or until the end of the study.</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1. Signed Informed consent 2. All patients should have the following disease criteria together MDS classified according to classical IPSS as intermediate 1 or low MDS classified according to revised IPSS at least intermediate Patients who failed to an approved treatment which can be EPO, lenalidomide or Vidaza® or who are not eligible for such a treatment or who have thrombocytopenia &lt; 20 G/L requiring transfusion or neutropenia &lt; 0.5 G/L associated with severe infection (defined as requiring hospitalization) 3. Age ≥ 45 and &lt; 70 years 4. Patient for whom a transplantation from a matched donor, (8/8 (HLA A, B, C, DRB1) identical at molecular level)unrelated donor or matched sibling), is considered irrespective of donor availability 5. Performance status 02 on the Eastern Cooperative Oncology Group (ECOG) Scale (At time of screening) 6. Negative pregnancy and adequate contraception (including in male patients wishing to father), if relevant. 7. Washout of at least 30 days since a previous treatment with Vidaza, Lenalidomide, EPO or any other treatment inducing cytopenias. 1. MDS classified according to classical IPSS as intermediate 2 or High risk 2. Transformation in Acute myeloid Leukemia (AML) 3. Severe active infection or any other uncontrolled severe condition. 4. Organ dysfunctions including the following Hepatic : total bilirubin &gt; 2 times upper limit of normal (ULN) (except moderate unconjugated hyperbilirubinemia due to intra medullary hemolysis or Gilbert syndrome) , alanine transaminase (ALT) and aspartate transaminase (AST) &gt; 3xULN Symptomatic respiratory chronic failure Symptomatic cardiac failure Renal clearance &lt; 60ml/min 5. Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or other tumors if not active during the last 3 years)</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Low risk MDS</keyword>
	<keyword>Transplantation</keyword>
</DOC>